263 related articles for article (PubMed ID: 9443934)
1. Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin.
Bailly C; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M; Waring MJ
Mol Pharmacol; 1998 Jan; 53(1):77-87. PubMed ID: 9443934
[TBL] [Abstract][Full Text] [Related]
2. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
3. Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Bailly C; Qu X; Anizon F; Prudhomme M; Riou JF; Chaires JB
Mol Pharmacol; 1999 Feb; 55(2):377-85. PubMed ID: 9927631
[TBL] [Abstract][Full Text] [Related]
4. Calories from carbohydrates: energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition.
Bailly C; Qu X; Graves DE; Prudhomme M; Chaires JB
Chem Biol; 1999 May; 6(5):277-86. PubMed ID: 10322124
[TBL] [Abstract][Full Text] [Related]
5. Sequence-selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove.
Bailly C; Braña M; Waring MJ
Eur J Biochem; 1996 Aug; 240(1):195-208. PubMed ID: 8797854
[TBL] [Abstract][Full Text] [Related]
6. DNA targeting of two new antitumour rebeccamycin derivatives.
Facompré M; Baldeyrou B; Bailly C; Anizon F; Marminon C; Prudhomme M; Colson P; Houssier C
Eur J Med Chem; 2002 Dec; 37(12):925-32. PubMed ID: 12660017
[TBL] [Abstract][Full Text] [Related]
7. Rebeccamycin analogues from indolo[2,3-c]carbazole.
Voldoire A; Sancelme M; Prudhomme M; Colson P; Houssier C; Bailly C; Léonce S; Lambel S
Bioorg Med Chem; 2001 Feb; 9(2):357-65. PubMed ID: 11249128
[TBL] [Abstract][Full Text] [Related]
8. DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
Facompre M; Carrasco C; Colson P; Houssier C; Chisholm JD; Van Vranken DL; Bailly C
Mol Pharmacol; 2002 Nov; 62(5):1215-27. PubMed ID: 12391286
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents.
Prudhomme M
Curr Med Chem; 2000 Dec; 7(12):1189-212. PubMed ID: 11032967
[TBL] [Abstract][Full Text] [Related]
10. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
11. Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Arimondo PB; Bailly C; Boutorine AS; Moreau P; Prudhomme M; Sun JS; Garestier T; Hélène C
Bioconjug Chem; 2001; 12(4):501-9. PubMed ID: 11459453
[TBL] [Abstract][Full Text] [Related]
12. Formaldehyde-induced alkylation of a 2'-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA.
Bailly C; Goossens JF; Laine W; Anizon F; Prudhomme M; Ren J; Chaires JB
J Med Chem; 2000 Nov; 43(24):4711-20. PubMed ID: 11101362
[TBL] [Abstract][Full Text] [Related]
13. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
14. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
15. Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
Arimondo PB; Bailly C; Boutorine A; Sun JS; Garestier T; Hélène C
C R Acad Sci III; 1999 Sep; 322(9):785-90. PubMed ID: 10547719
[TBL] [Abstract][Full Text] [Related]
16. DNA sequence recognition by bispyrazinonaphthalimides antitumor agents.
Carrasco C; Joubert A; Tardy C; Maestre N; Cacho M; Braña MF; Bailly C
Biochemistry; 2003 Oct; 42(40):11751-61. PubMed ID: 14529286
[TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and interaction with purified membranes of rebeccamycin derivatives.
Goossens JF; Hénichart JP; Anizon F; Prudhomme M; Dugave C; Riou J; Bailly C
Eur J Pharmacol; 2000 Feb; 389(2-3):141-6. PubMed ID: 10688977
[TBL] [Abstract][Full Text] [Related]
18. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I.
Qu X; Chaires JB; Ohkubo M; Yoshinari T; Nishimura S; Bailly C
Anticancer Drug Des; 1999 Oct; 14(5):433-42. PubMed ID: 10766298
[TBL] [Abstract][Full Text] [Related]
19. DNA binding properties of the indolocarbazole antitumor drug NB-506.
Carrasco C; Vezin H; Wilson WD; Ren J; Chaires JB; Bailly C
Anticancer Drug Des; 2001; 16(2-3):99-107. PubMed ID: 11962518
[TBL] [Abstract][Full Text] [Related]
20. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Moreau P; Anizon F; Sancelme M; Prudhomme M; Bailly C; Carrasco C; Ollier M; Sevère D; Riou JF; Fabbro D; Meyer T; Aubertin AM
J Med Chem; 1998 May; 41(10):1631-40. PubMed ID: 9572888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
